<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885182</url>
  </required_header>
  <id_info>
    <org_study_id>OXN10-CN-303</org_study_id>
    <nct_id>NCT01885182</nct_id>
  </id_info>
  <brief_title>Targin Cancer Pain</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets 5/2.5mg, 10/5mg, 20/10mg or 40/20mg Compared to Oxycodone PR 5mg, 10mg, 20mg or 40mg in Subjects With Moderate to Severe, Chronic Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Pte Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets
      compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, double-dummy, parallel group study using OXN and OXY PR
      to treat moderate to severe, chronic cancer pain. Subjects with documented history of cancer
      pain that requires around the clock opioid therapy will be included. Subjects must have a
      medical history of constipation that was induced by, or worsened by their opioid therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>BFI-Bowel Function Index</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPI-Brief Pain Index</measure>
    <time_frame>4 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate patient quality of life based on EQ-5D-4 weeks To compare the improvement in symptoms of constipation in subjects receiving treatment with OXN compared to OXY PR based on laxative use - 4 weeks To demonstrate the comparability of OXN compared to OXY PR for the management of chronic cancer pain as assessed by rescue medication use recorded by subjects. 4 weeks To assess safety of treatment with OXN compared with OXYPR based on the Modified Subjective Opiate Withdrawal Scale (SOWS), Adverse Events (AEs), Electrocardiograms (ECG) and laboratory tests 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Oxycodone/Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5/2.5mg, 10/5mg, 20/10mg or 40/20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg, 10mg, 20mg or 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/Naloxone</intervention_name>
    <arm_group_label>Oxycodone/Naloxone</arm_group_label>
    <other_name>Targin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          1. Males &amp; females, at least 18 years or older with a diagnosis of cancer.

          2. Females less than one year post-menopausal must have a negative urine pregnancy test
             recorded prior to the first dose of study medication, be non-lactating, &amp; willing to
             use adequate &amp; highly effective method of contraception throughout the study. Highly
             effective methods of birth control are defined as those which result in a low failure
             rate (i.e. less than 1% per year) when used consistently correctly such as
             sterilisation, implants, injectables, combined oral contraceptives, some IUDs
             (hormonal), sexual abstinence or vasectomised partner.

          3. Subjects who are receiving WHO step II or Step III analgesic medication who have
             constipation induced, or worsened by their opioid medication, as shown by

               1. the subject's medical need of regular intake of laxatives to have at least 3
                  bowel evacuations per week, or having less than 3 bowel evacuations when not
                  taking a laxative, respectively.

               2. the subject's self-assessment that their constipation was induced or worsened by
                  their current pre-study opioid medication.

          4. Documented history of moderate to severe, chronic cancer pain that requires around
             the-clock opioid therapy (starting dose of oxycodone PR between 20-80 mg/day) &amp; are
             likely to benefit from WHO step III opioid therapy for the duration of the study.
             Subjects must be willing to discontinue their current opioid analgesic routine.

          5. Opioid medication continue at a stable or nearly stable dose in the investigator's
             opinion during the treatment.

          6. Subjects are willing to discontinue pre study laxative medication &amp; take study
             specific laxative medication.

          7. Subjects taking daily fibre supplementation or bulking agents are eligible if they
             can be maintained on a stable dose &amp; regimen throughout the study, &amp; in the
             investigators opinion are willing &amp; able to maintain adequate hydration.

          8. Subjects willing &amp; able (e.g. mental &amp; physical condition) to participate in all
             aspects of the study, including use of medication, completion of subjective
             evaluations, attending scheduled clinic visits, completing telephone contacts, &amp;
             compliance with protocol requirements as evidenced by providing written, informed
             consent.

          9. Subjects already taking non-opioid analgesics &amp; all other concomitant medications
             (including those for the treatment of depression) are eligible to take part in the
             study. However, all concomitant medications that are considered necessary for the
             subject's welfare should be continued at a stable dose throughout the double-blind
             phase of the study &amp; under the supervision of the investigator.

         10. Expected survival time &gt; 3 months.

         11. With capability of reading, understanding &amp; signing inform consent form &amp; compliance
             with protocol requirements.

        Exclusion

          1. Subjects that require a dose &gt;80 mg/day oxycodone PR at the start of the double-blind
             phase.

          2. Any history of hypersensitivity to oxycodone, naloxone, morphine, bisacodyl, related
             products &amp; other ingredients.

          3. Subjects with any situation in which opioids are contra-indicated, severe respiratory
             depression with hypoxia &amp; or hypercapnia, severe chronic obstructive pulmonary
             disease, cor pulmonal, severe bronchial asthma, paralytic ileus.

          4. Subjects with evidence of clinically significant gastrointestinal disease (e.g.
             paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the
             gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related
             to the underlying cancer or disease progression.

          5. Evidence of clinically significant cardiovascular, renal, hepatic or psychiatric
             disease, as determined by medical history, clinical laboratory tests, ECG results &amp;
             physical examination, that would place the subject at risk upon exposure to the study
             medication or that may confound the analysis &amp; or interpretation of the study
             results.

          6. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT;
             SGPT), r-glutamyltransferase (GGT) or alkaline phosphatase levels (&gt;3 times the upper
             limit of normal) or an abnormal total bilirubin &amp; or creatinine level(s) (greater
             than 1.5 times the upper limit of normal).

          7. Cyclic chemotherapy in the two weeks before the screening visit or planned during the
             core study that has shown in the past to influence bowel function. If subjects are
             having their first cycle of chemotherapy during the 2 weeks before the screening
             visit or during the double-blind phase of the study they should be excluded from the
             study.

          8. Radiotherapy that, in the investigators opinion, would influence bowel function or
             pain during the double-blind phase of the study.

          9. Subjects with known or suspected unstable brain metastases or spinal cord compression
             that may require changes in steroid treatment throughout the duration of the study.

         10. Subjects with uncontrolled seizures.

         11. Subjects with increased intracranial pressure.

         12. In the investigator's opinion, subjects who are receiving hypnotics or other central
             nervous system (CNS) depressants that may pose a risk of additional CNS depression
             with opioid study medication.

         13. Subjects with myxoedema, not adequately treated hypothyroidism or Addisons disease.

         14. Subjects who have a confirmed diagnosis of ongoing irritable bowel syndrome(IBS).

         15. Surgery completed within 4 weeks prior to the start of the Screening Period, or
             planned surgery during the study that would influence pain or bowel function during
             the study or preclude completion of the study.

         16. Subjects receiving opioid substitution therapy for opioid addiction (e.g. methadone
             or buprenorphine).

         17. Active alcohol or drug abuse &amp; or history of opioid abuse.

         18. Subjects suffering from diarrhoea &amp; or opioid withdrawal.

         19. Subjects presently taking, or who have taken, naloxone â‰¤30 days prior to the start of
             the Screening Period.

         20. Subjects who participated in a clinical research study involving a new chemical
             entity or an experimental drug within 30 days of study entry (defined as the start of
             the Screening Period), unless the subject is on data collection phase for Overall
             Survival.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao Bangwei, Dr</last_name>
      <phone>+86 10 6313 8655</phone>
      <email>bangweicao@yahoo.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>June 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
